Protease nexin-1 inhibitor for the treatment of haemorrhagic disease

The thrombogram of FVIII-KO mice displays a prolonged time to peak and a reduced peak thrombin. The addition of the neutralizing anti-protease nexin-1 (PN-1) antibody enhances thrombin generation in PRP from haemophilia mice. The thrombogram of patient with haemophilia displays prolonged lag time and time to peak and a reduced peak thrombin and a reduced endogenous thrombin potential. As observed with the addition of recombinant FVIII, the neutralizing anti-PN-1 antibody enhances thrombin generation in PRP from patients with haemophilia A. Anti-PN-1 antibody improves thrombin generation in mild and moderate haemophilia patients but not in severe haemophilia patients. These findings establish a requirement for PN-1 inhibition as a specific anticoagulant in platelets and demonstrated that blocking PN-1 have a role in haemorrhagic disease treatment.

Keywords: Protease nexin-1, Haemophilia
Patent Application number: EP15305544.7
Marie-christine BOUTONChristophe OLIVIEROlivier CHRISTOPHECécile DENISPeter LENTING



Business Developper
Aymeric Empereur
Aymeric Empereur
Business Developer
Patent filling date: 2015-04-15
Rare disease: Yes

You might also be interested in